Ting Therapeutics Advances TT004 into Phase Ib Clinical Trials as a Potential Cisplatin Chemoprotective Therapy
Oct 23, 2026
San Diego, California Oct 22, 2026 (Issuewire.com) - Ting Therapeutics Advances TT004 into Phase Ib Clinical Trial as a Potential Chemoprotective Therapy for Cisplatin-Treated Patients
- China IND Approved;
- Phase Ib Trial Set to Begin Recruiting Patients at Eye and ENT Hospital of Fudan University in Shanghai
Ting Therapeutics, Inc., a biotechnology company developing therapies for treatment-related tissue injury, today announced that its lead candidate, TT004, has received IND approval in China and is advancing into Phase Ib clinical development as a potential chemoprotective therapy for patients receiving cisplatin chemotherapy.
Cisplatin is a highly effective cancer treatment, but its toxicities can substantially limit therapy. Approximately 40% of patients discontinue or modify chemotherapy because of treatment-related toxicities. Cisplatin can also cause permanent hearing loss in up to 80% of patients and acute kidney injury in approximately 30% of patients.
TT004 is designed to protect normal tissues from cisplatin toxicity while preserving its anticancer activity. In preclinical studies, TT004 increased survival following cisplatin exposure three-fold and reduced cisplatin-induced hearing loss and kidney injury by approximately 70%, without compromising cisplatin's anticancer effects.
"These findings support our vision of TT004 as a chemoprotective therapy that could improve the tolerability of cisplatin while maintaining its anticancer efficacy," said Jian Zuo, PhD, Co-Founder and CEO of Ting Therapeutics. "Our goal is to reduce the suffering caused by cisplatin treatment-related toxicities, help more patients receive and complete effective chemotherapy, and improve their long-term quality of life."
Ting Therapeutics recently licensed its China rights for TT004 to Rising Dragon, a Chinese biotechnology company, for development in China. The companies jointly developed TT004 as an oral tablet and obtained IND approval from China's Center for Drug Evaluation (CDE) for first-in-human clinical evaluation.
The Phase Ib trial, conducted in collaboration with oncologists and otolaryngologists at Eye and ENT Hospital of Fudan University in Shanghai, will evaluate the safety and tolerability of oral TT004 administered with standard-of-care cisplatin chemotherapy in patients with head and neck cancer. The study has received institutional ethics approval and is preparing to initiate patient recruitment.
TT004's protective effects have been demonstrated only in preclinical models and have not yet been shown in humans. This trial is the first clinical evaluation of TT004 and an important step toward determining whether these effects can be translated to cancer patients.
About Ting Therapeutics
Founded in 2018, Ting Therapeutics, Inc. develops novel and repurposed therapeutics to prevent and treat hearing loss and other treatment-related tissue injuries. The Company's pipeline targets hearing loss associated with chemotherapy, noise exposure, antibiotics, aging, and other causes.
Contact:
Jian Zuo, PhD, Co-Founder & CEO
Ting Therapeutics, Inc.
6868 Nancy Ridge Dr., San Diego, CA 92121
[email protected]
Source :Ting Therapeutics, Inc.
This article was originally published by IssueWire. Read the original article here.
More News
Natalie Nunn Dresses Up as North West for Halloween 2026, Aspiring Rapper Reacts After She Transformed Into ‘Bad Girls Club’ Star
Natalie Nunn returned the favor for Halloween! The 41-year-old Bad Girls Club star just shared a new video on Instagram, […] The post Natalie Nunn Dresses Up as North West for Halloween 2026, Aspiring Rapper Reacts After She Transformed Into ‘Bad Girls Club’ Star appeared first on Just Jared - Celebrity News, Entertainment News & Photos.
How Did Hilary Swank Hide Her Pregnancy? Actress Reveals How She Kept Her Big News a Secret for Months
Hilary Swank is dishing on her pregnancy! The 52-year-old actress recently announced that she is pregnant and expecting her third […] The post How Did Hilary Swank Hide Her Pregnancy? Actress Reveals How She Kept Her Big News a Secret for Months appeared first on Just Jared - Celebrity News, Entertainment News & Photos.
‘Clayface’ Cashing In $3.5M+ Thursday Previews – Box Office
EXCLUSIVE: Peter Safran and James Gunn’s DC entree into lower budget genre movies, Clayface, is off to a solid start in previews tonight with an estimated $3.5M, if not more. Domestic weekend forecasts are between $20M-$25M, which if that occurs, would deliver the newly combined Paramount-Warner Bros its second back-to-back No. 1 opener at the […]
‘Nobody Wants This’ Creator Erin Foster Reacts to Adam Brody’s Comments Criticizing Israel
Adam Brody recently showed support for the “Free Palestine” movement and now Nobody Wants This creator Erin Foster is reacting […] The post ‘Nobody Wants This’ Creator Erin Foster Reacts to Adam Brody’s Comments Criticizing Israel appeared first on Just Jared - Celebrity News, Entertainment News & Photos.
Biographies of John Williams and Bernard Herrmann Among Honored Works in ASCAP’s Awards for Music Writing and Broadcasts
The winners of annual awards given out by ASCAP for the year’s most outstanding music writing and broadcasts include biographies of film composers John Williams and Bernard Herrmann, as well as a documentary about cult R&B artist Swamp Dogg, liner notes for an archival release from Frank Zappa, Rick Beato’s YouTube podcasts, and books about […]
Riding Boots Are the Equestrian Chic Trend Taking Over Fall
Every year a new boot style emerges as fall's supreme shoe. This year, fashion is channeling their inner horse girl by embracing the timeless riding boot. With the rise of the barn jacket and the...
NY Times Revisits Elizabeth Holmes Quote After ‘You Can See Everything’ Release, Shares New Update from Reporter
One of the recurring topics throughout the three-hour documentary You Can See Everything is an interview that Elizabeth Holmes did […] The post NY Times Revisits Elizabeth Holmes Quote After ‘You Can See Everything’ Release, Shares New Update from Reporter appeared first on Just Jared - Celebrity News, Entertainment News & Photos.
Is ‘Wildwood’ a Kids Movie? Why the Animated Film is Rated PG-13
Wildwood is hitting theaters this weekend, but parents of children may be wary of taking their kids to a PG-13 […] The post Is ‘Wildwood’ a Kids Movie? Why the Animated Film is Rated PG-13 appeared first on Just Jared - Celebrity News, Entertainment News & Photos.
Tom Skerritt Dead at 93: Costar Julia Roberts Pays Tribute
Tom Skerritt is being fondly remembered by his family and friends. The film and TV actor, known for his roles in hits like Top Gun and M*A*S*H, died Oct. 21 of natural causes, according to his...
Richard Gadd, Bill Camp and Ray McKinnon Join Michael Keaton-Directed Western ‘Rode to Ruin’ (EXCLUSIVE)
Emmy Award-winning actor and writer Richard Gadd, multi-Emmy and SAG nominated actor Bill Camp and Oscar-nominated filmmaker and actor Ray McKinnon are joining “Rode to Ruin,” a Western thriller directed by Michael Keaton. Keaton also stars in the film, which is now in production in Santa Fe, New Mexico, along with Morgan Freeman and Laura […]
A Sparkling ‘Imaginary Invalid,’ With Bill Irwin, Is the Cure for What Ails You
Bill Irwin, who may well be our greatest living clown, stars in his own adaptation of Molière’s 1673 play about a domineering hypochondriac paterfamilias.
‘The Imaginary Invalid’ Broadway Review: Molière Gets Clowned By A Winning Bill Irwin
The La-Z-Boy-style brown leather recliner that’s a focal point of Bill Irwin’s The Imaginary Invalid opening tonight on Broadway doesn’t really mesh with the eye-popping 17th Century French frills and finery that suggest a stage invasion of brilliantly plumed vainglorious peacocks, but no matter. Irwin knows how to clown an audience, and in this enjoyable, […]
Recommended
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.